Kim, W. Seog., Shortt, J., Zinzani, P. L., Mikhailova, N., Radeski, D., Ribrag, V., Domingo Domenech, E., Sawas, A., Alexis, K., Emig, M., Elbadri, R., Hajela, P., Ravenstijn, P., Pinto, S., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2024). A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-1913

Iwamoto, F. M., Tanguturi, S. K., Nayak, L., Wang, T. J., Desai, A., Lustig, R. A., Bagley, S., Wong, E. T., Hertan, L. M., McCluskey, C., Hayden, J., Muzikansky, A., Nakhawa, S., Japo, J., Bossi, C. C., Meylan, M., Tian, Y., Barlow, G. L., Speliakos, P., … Reardon, D. A. (2024). Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma. Clinical Cancer Research, OF1–OF12. https://doi.org/10.1158/1078-0432.ccr-24-1629

Dallos, M. C., Obradovic, A. Z., McCann, P., Chowdhury, N., Pratapa, A., Aggen, D. H., Gaffney, C., Autio, K. A., Virk, R. K., De Marzo, A. M., Antonarakis, E. S., Scher, H. I., Drake, C. G., & Rathkopf, D. E. (2024). Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. Clinical Cancer Research, 30(22), 5218–5230. https://doi.org/10.1158/1078-0432.ccr-24-0060

Ma, K. L., Mitchell, T. C., Dougher, M., Sharon, C. E., Tortorello, G. N., Elder, D. E., Morgan, E. E., Gimotty, P. A., Huang, A. C., Amaravadi, R. K., Schuchter, L. M., Flowers, A., Miura, J. T., Karakousis, G. C., & Xu, X. (2024). Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clinical Cancer Research, 30(21), 4987–4994. https://doi.org/10.1158/1078-0432.ccr-23-3775

Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., Jenkins, R. W., Haq, R., Jager, M. J., Wang, X., Ryeom, S., & Ferrone, C. R. (2024). Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clinical Cancer Research, 30(15), 3243–3258. https://doi.org/10.1158/1078-0432.ccr-24-0071

Luthria, K., Shah, P., Caldwell, B., Melms, J. C., Abuzaid, S., Jakubikova, V., Brodtman, D. Z., Bose, S., Amin, A. D., Ho, P., Biermann, J., Tagore, S., Ingham, M., Schwartz, G. K., & Izar, B. (2024). Single-cell profiling of sarcomas from archival tissue reveals programs associated with resistance to immune checkpoint blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-2976

Lenis, A. T., Ravichandran, V., Brown, S., Alam, S. M., Katims, A., Truong, H., Reisz, P. A., Vasselman, S., Nweji, B., Autio, K. A., Morris, M. J., Slovin, S. F., Rathkopf, D., Danila, D., Woo, S., Vargas, H. A., Laudone, V. P., Ehdaie, B., Reuter, V., … Abida, W. (2024). Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. Clinical Cancer Research, OF1–OF10. https://doi.org/10.1158/1078-0432.ccr-23-3403

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., Lu, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Wang, Y., Go, H., Ponzoni, M., Ferreri, A. J. M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clinical Cancer Research, 29(23), 4808–4821. https://doi.org/10.1158/1078-0432.ccr-23-1554

Guercio, B. J., Sarfaty, M., Teo, M. Y., Ratna, N., Duzgol, C., Funt, S. A., Lee, C.-H., Aggen, D. H., Regazzi, A. M., Chen, Z., Lattanzi, M., Al-Ahmadie, H. A., Brannon, A. R., Shah, R., Chu, C., Lenis, A. T., Pietzak, E., Bochner, B. H., Berger, M. F., … Iyer, G. (2023). Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. Clinical Cancer Research, 29(22), 4586–4595. https://doi.org/10.1158/1078-0432.ccr-23-1283

Paolino, J., Dimitrov, B., Apsel Winger, B., Sandoval-Perez, A., Rangarajan, A. V., Ocasio-Martinez, N., Tsai, H. K., Li, Y., Robichaud, A. L., Khalid, D., Hatton, C., Gillani, R., Polonen, P., Dilig, A., Gotti, G., Kavanagh, J., Adhav, A. A., Gow, S., Tsai, J., … Pikman, Y. (2023). Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clinical Cancer Research, 29(22), 4613–4626. https://doi.org/10.1158/1078-0432.ccr-22-2562

Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research, 29(21), 4399–4407. https://doi.org/10.1158/1078-0432.ccr-23-1295

Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., Trinh, T., Mattie, M., Neumann, F., Kim, J. J., To, C., Filosto, S., & Reshef, R. (2023). Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11. Clinical Cancer Research, 29(20), 4118–4127. https://doi.org/10.1158/1078-0432.ccr-23-0916

Johnson, M., Bell, A., Lauing, K. L., Ladomersky, E., Zhai, L., Penco-Campillo, M., Shah, Y., Mauer, E., Xiu, J., Nicolaides, T., Drumm, M., McCortney, K., Elemento, O., Kim, M., Bommi, P., Low, J. T., Memon, R., Wu, J., Zhao, J., … Wainwright, D. A. (2023). Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clinical Cancer Research, 29(23), 4973–4989. https://doi.org/10.1158/1078-0432.ccr-23-0834

Ingham, M., Lee, S., Van Tine, B. A., Choy, E., Oza, J., Doshi, S., Ge, L., Oppelt, P., Cote, G., Corgiat, B., Sender, N., Sta Ana, S., Panchalingam, L., Petricoin, E., & Schwartz, G. K. (2022). A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma. Clinical Cancer Research, 29(6), 1031–1039. https://doi.org/10.1158/1078-0432.ccr-22-3351

Sivakumar, S., Jin, D. X., Rathod, R., Ross, J., Cantley, L. C., Scaltriti, M., Chen, J. W., Hutchinson, K. E., Wilson, T. R., Sokol, E. S., & Vasan, N. (2023). Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 29(6), 1125–1136. https://doi.org/10.1158/1078-0432.ccr-22-2270

Mezghani, N., Yao, A., Vasilyeva, D., Kaplan, N., Shackelford, A., Yoon, A., Phillipone, E., Dubey, S., Schwartz, G. K., Taylor, A. M., & Momen-Heravi, F. (2022). Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry. Clinical Cancer Research, 29(5), 910–920. https://doi.org/10.1158/1078-0432.ccr-22-2258

Peng, K., Zhang, F., Wang, Y., Sahgal, P., Li, T., Zhou, J., Liang, X., Zhang, Y., Sethi, N., Liu, T., Zhang, H., & Bass, A. J. (2022). Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer. Clinical Cancer Research, 29(1), 197–208. https://doi.org/10.1158/1078-0432.ccr-22-1609

Shankar, L. K., Huang, E., Litiere, S., Hoekstra, O. S., Schwartz, L., Collette, S., Boellaard, R., Bogaerts, J., Seymour, L., & deVries, E. G. E. (2022). Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response. Clinical Cancer Research, 29(1), 143–153. https://doi.org/10.1158/1078-0432.ccr-21-3143

Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S., Sachsenmeier, K. F., Russell, D. L., Moorthy, G., Sidders, B. S., Pilling, E. A., Chen, H., Hattersley, M. M., Das, M., Kumar, R., Pouliot, G. P., & Patel, M. R. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research, 28(22), 4871–4884. https://doi.org/10.1158/1078-0432.ccr-22-0612

Goldman, J. W., Piha-Paul, S. A., Curti, B., Pedersen, K. S., Bauer, T. M., Groenland, S. L., Carvajal, R. D., Chhaya, V., Kirby, G., McGlinchey, K., Hammond, S. A., Streicher, K., Townsley, D. M., Chae, Y. K., Voortman, J., Marabelle, A., & Powderly, J. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 28(17), 3709–3719. https://doi.org/10.1158/1078-0432.ccr-21-3016

Gaydosik, A. M., Stonesifer, C. J., Khaleel, A. E., Geskin, L. J., & Fuschiotti, P. (2022). Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas. Clinical Cancer Research, 28(12), 2610–2622. https://doi.org/10.1158/1078-0432.ccr-21-4437

Lassman, A. B., Sepúlveda-Sánchez, J. M., Cloughesy, T. F., Gil-Gil, M. J., Puduvalli, V. K., Raizer, J. J., De Vos, F. Y. F., Wen, P. Y., Butowski, N. A., Clement, P. M. J., Groves, M. D., Belda-Iniesta, C., Giglio, P., Soifer, H. S., Rowsey, S., Xu, C., Avogadri, F., Wei, G., Moran, S., & Roth, P. (2022). Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clinical Cancer Research, 28(11), 2270–2277. https://doi.org/10.1158/1078-0432.ccr-21-2664

Obradovic, A., Graves, D., Korrer, M., Wang, Y., Roy, S., Naveed, A., Xu, Y., Luginbuhl, A., Curry, J., Gibson, M., Idrees, K., Hurley, P., Jiang, P., Liu, X. S., Uppaluri, R., Drake, C. G., Califano, A., & Kim, Y. J. (2022). Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer. Clinical Cancer Research, 28(10), 2094–2109. https://doi.org/10.1158/1078-0432.ccr-21-3570

Rosenblat, T. L., McDevitt, M. R., Carrasquillo, J. A., Pandit-Taskar, N., Frattini, M. G., Maslak, P. G., Park, J. H., Douer, D., Cicic, D., Larson, S. M., Scheinberg, D. A., & Jurcic, J. G. (2022). Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical Cancer Research, 28(10), 2030–2037. https://doi.org/10.1158/1078-0432.ccr-21-3712

Nguyen, T. T. T., Shang, E., Schiffgens, S., Torrini, C., Shu, C., Akman, H. O., Prabhu, V. V., Allen, J. E., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2022). Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical Cancer Research, 28(9), 1881–1895. https://doi.org/10.1158/1078-0432.ccr-21-2857

Gounder, M. M., Rosenbaum, E., Wu, N., Dickson, M. A., Sheikh, T. N., D’Angelo, S. P., Chi, P., Keohan, M. L., Erinjeri, J. P., Antonescu, C. R., Agaram, N., Hameed, M. R., Martindale, M., Lefkowitz, R. A., Crago, A. M., Singer, S., Tap, W. D., Takebe, N., Qin, L.-X., & Schwartz, G. K. (2022). A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma. Clinical Cancer Research, 28(8), 1586–1594. https://doi.org/10.1158/1078-0432.ccr-21-3874

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617

Xu-Monette, Z. Y., Wei, L., Fang, X., Au, Q., Nunns, H., Nagy, M., Tzankov, A., Zhu, F., Visco, C., Bhagat, G., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Sun, X., Han, X., Go, H., … Young, K. H. (2022). Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 28(5), 972–983. https://doi.org/10.1158/1078-0432.ccr-21-2949

Viny, A. D. (2021). DNMT3A-Mutant Leukemia Cells Primed to “Fork It Over” under DNA Damage. Clinical Cancer Research, 28(4), 573–575. https://doi.org/10.1158/1078-0432.ccr-21-3949

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., Wu, J., Dubensky, T. W., McWhirter, S. M., Müller, T., Nair, N., & Luke, J. J. (2021). Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 28(4), 677–688. https://doi.org/10.1158/1078-0432.ccr-21-1963

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Lassman, A. B., Wen, P. Y., van den Bent, M. J., Plotkin, S. R., Walenkamp, A. M. E., Green, A. L., Li, K., Walker, C. J., Chang, H., Tamir, S., Henegar, L., Shen, Y., Alvarez, M. J., Califano, A., Landesman, Y., Kauffman, M. G., Shacham, S., & Mau-Sørensen, M. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research, 28(3), 452–460. https://doi.org/10.1158/1078-0432.ccr-21-2225

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275